Novo’s race to rejuvenate its cardiometabolic portfolio has seen the rebranded Danish pharma pen a $1.4 biobucks pact with ...

A phase 2b study of Longeveron’s stem cell therapy in a pediatric heart disease has missed its primary endpoint, prompting ...

Novartis has extended its losing streak, stopping an amyotrophic lateral sclerosis (ALS) program after flunking a phase 2 ...

Following a steady stream of acquisitions that culminated in three biotech buyouts earlier this year, Gilead Sciences’ CEO ...

Sling Therapeutics has closed a $123 million series C round to advance its oral therapy for thyroid eye disease (TED) through a phase 3 trial and hopefully on to commercialization. | Sling ...

Connect Biopharma’s hopes of dethroning Dupixent took a knock as its IL-4/IL-13 blocker missed the primary endpoint of a ...

GSK has bet up to $750 million on a Chimagen Biosciences trispecific T-cell engager, positioning the Big Pharma to start ...

After teasing a new initiative to speed up early-stage clinical trials over the summer, the FDA today opened a pilot program ...

To keep the resources flowing to this new strategy, Sionna is reducing its headcount by around 46%, including the departure ...

A phase 2 trial of Johnson & Johnson’s JNJ-5120 has missed its primary endpoint, denting the prospects of the Contineum ...

With Novo axing monlunabant, Corbus has a chance to establish CRB-913 as the frontrunner in the CB1 race. The phase 1b data ...

Axoltis Pharma announced today that its phase 2 trial for amyotrophic lateral sclerosis (ALS) has missed its primary endpoint ...